878 related articles for article (PubMed ID: 25818419)
21. Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel.
Sahu PK; Mishra DK; Jain N; Rajoriya V; Jain AK
Drug Dev Ind Pharm; 2015 Apr; 41(4):640-9. PubMed ID: 24564799
[TBL] [Abstract][Full Text] [Related]
22. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
23. Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance.
Lei M; Ma G; Sha S; Wang X; Feng H; Zhu Y; Du X
Drug Deliv; 2019 Dec; 26(1):262-272. PubMed ID: 30856352
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals.
Men Y; Wang XX; Li RJ; Zhang Y; Tian W; Yao HJ; Ju RJ; Ying X; Zhou J; Li N; Zhang L; Yu Y; Lu WL
Int J Nanomedicine; 2011; 6():3125-37. PubMed ID: 22163164
[TBL] [Abstract][Full Text] [Related]
25. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis.
Wang H; Zhang F; Wen H; Shi W; Huang Q; Huang Y; Xie J; Li P; Chen J; Qin L; Zhou Y
J Nanobiotechnology; 2020 Jan; 18(1):8. PubMed ID: 31918714
[TBL] [Abstract][Full Text] [Related]
26. iRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance.
Shen J; Meng Q; Sui H; Yin Q; Zhang Z; Yu H; Li Y
Mol Pharm; 2014 Aug; 11(8):2579-91. PubMed ID: 24236909
[TBL] [Abstract][Full Text] [Related]
27. PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer.
Ju RJ; Cheng L; Xiao Y; Wang X; Li CQ; Peng XM; Li XT
J Liposome Res; 2018 Sep; 28(3):236-248. PubMed ID: 28480778
[TBL] [Abstract][Full Text] [Related]
28. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
Ji X; Gao Y; Chen L; Zhang Z; Deng Y; Li Y
Int J Pharm; 2012 Jan; 422(1-2):390-7. PubMed ID: 22001531
[TBL] [Abstract][Full Text] [Related]
29. CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels.
Hu Q; Gao X; Kang T; Feng X; Jiang D; Tu Y; Song Q; Yao L; Jiang X; Chen H; Chen J
Biomaterials; 2013 Dec; 34(37):9496-508. PubMed ID: 24054848
[TBL] [Abstract][Full Text] [Related]
30. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells.
Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
Drug Deliv; 2012 May; 19(4):169-76. PubMed ID: 22506922
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer.
Wang RH; Cao HM; Tian ZJ; Jin B; Wang Q; Ma H; Wu J
Oncol Rep; 2015 Feb; 33(2):783-91. PubMed ID: 25482610
[TBL] [Abstract][Full Text] [Related]
32. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z
Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814
[TBL] [Abstract][Full Text] [Related]
33. A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer.
Chen M; Song F; Liu Y; Tian J; Liu C; Li R; Zhang Q
Nanoscale; 2019 Mar; 11(9):3814-3826. PubMed ID: 30600823
[TBL] [Abstract][Full Text] [Related]
34. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel.
Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Guo X; Chen D
Int J Pharm; 2015 Mar; 480(1-2):116-27. PubMed ID: 25615984
[TBL] [Abstract][Full Text] [Related]
35. Reversal of multidrug resistance in human lung cancer cells by delivery of 3-octadecylcarbamoylacrylic acid-cisplatin-based liposomes.
Song J; Ren W; Xu T; Zhang Y; Guo H; Zhu S; Yang L
Drug Des Devel Ther; 2017; 11():441-449. PubMed ID: 28255230
[TBL] [Abstract][Full Text] [Related]
36. Systemic delivery of micelles loading with paclitaxel using N-succinyl-palmitoyl-chitosan decorated with cRGDyK peptide to inhibit non-small-cell lung cancer.
Yuan ZQ; Li JZ; Liu Y; Chen WL; Yang SD; Zhang CG; Zhu WJ; Zhou XF; Liu C; Zhang XN
Int J Pharm; 2015 Aug; 492(1-2):141-51. PubMed ID: 26188316
[TBL] [Abstract][Full Text] [Related]
37. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
38. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer.
Shen J; Yin Q; Chen L; Zhang Z; Li Y
Biomaterials; 2012 Nov; 33(33):8613-24. PubMed ID: 22910221
[TBL] [Abstract][Full Text] [Related]
39. Chitosan oligosaccharide modified liposomes enhance lung cancer delivery of paclitaxel.
Miao YQ; Chen MS; Zhou X; Guo LM; Zhu JJ; Wang R; Zhang XX; Gan Y
Acta Pharmacol Sin; 2021 Oct; 42(10):1714-1722. PubMed ID: 33469196
[TBL] [Abstract][Full Text] [Related]
40. A novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment.
Yuan X; Ji W; Chen S; Bao Y; Tan S; Lu S; Wu K; Chu Q
Int J Nanomedicine; 2016; 11():2119-31. PubMed ID: 27307727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
